<DOC>
	<DOCNO>NCT00762710</DOCNO>
	<brief_summary>The purpose study determine whether drug prazosin effective treatment alcohol dependency .</brief_summary>
	<brief_title>Study Medication Prazosin Alcohol Dependence</brief_title>
	<detailed_description>Alcohol dependence ( AD ) afflict nearly 10 % US population cause marked medical morbidity mortality , mark psychiatric morbidity , increase health care cost , lose work hour ( Saxon , Malte , Sloan , et al. , 2006 ; McFall , Saxon , Thaneemit-Chen , et al. , 2007 ) . Alcohol dependence biologically , genetically base disease , yet majority clinically accept treatment behaviorally psychosocially base ( Anton , O'Malley , Ciraulo , et al. , 2006 ; Todd , Armeli , Tennen , et al. , 2005 ) . Despite initial success treatment , 40-70 % patient relapse within first 12 month treatment ( McGinnis &amp; Foege , 1993 ) . Research need develop effective biological treatment . Currently , three pharmacological treatment FDA approve treatment alcohol dependence sub-optimal . None medication directly target noradrenergic brain system . Recent advance understand neurobiology substance dependence relapse support notion adrenergic system play critical role process . In 6-week , double-blind , placebo-controlled pilot study , randomize 24 participant without PTSD enter treatment AD prazosin identical appear placebo ( Simpson et al. , 2009 ) . The prazosin group report adverse event placebo group , control drink per week baseline week number , prazosin group report few drink per week final 3 week study . These finding lead u conduct large trial evaluate prazosin AD . The current study 16-week , randomize , two group parallel-design , double-blind , placebo-controlled trial evaluate efficacy prazosin decrease alcohol use subjective experience alcohol crave individual without PTSD seek treatment AD . Following randomization , 2-week titration period follow 10 week stable dose prazosin placebo . Study participant attend study visit least weekly 12 week complete final follow-up one month discontinuation medication phase study 16 week post-randomization . All study participant also participate Medical Management ( MM ) treatment , behavioral intervention demonstrate efficacy behavioral platform treatment AD ( Anton , O'Malley , Ciraulo , et al. , 2006 ) . Study participant involve professional counseling substance abuse treatment study involvement , though 12-step meeting attendance encourage MM . Daily monitor alcohol craving , alcohol use , substance crave substance use , medication compliance , key psychiatric symptom via toll-free telephone call Interactive Voice Response ( IVR ) system continue throughout 16-week study . Outcome measure address alcohol use crave include IVR report crave use , TLFB alcohol use , Penn Alcohol Craving Scale ( PACS ) , Patient Health Questionnaire-9 ( depression ) , urine toxicology analysis ( UDA ) , Breathalyzer reading .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Prazosin</mesh_term>
	<criteria>Current primary DSMIV diagnosis alcohol dependence ( AD ) Heavy drinking last 30 day At least 18 year age Good general medical health ( see Exclusion Criteria ) Capacity provide inform consent English fluency literacy Psychiatric/behavioral : current posttraumatic stress disorder ( PTSD ) ; psychiatric disorder require medication antidepressant ; currently take disulfiram , acamprosate , naltrexone plan take medication 12week medication phase study ; current dependence psychoactive substance nicotine cannabis ; current diagnosis opioid abuse , use opioid containing medication benzodiazepine previous month , UDA positive opioids , benzodiazepine , sedative hypnotic . Medical : significant acute chronic medical illness ; woman pregnant , nurse infant ( ) , childbearing potential use contraceptive method judge study physician PA effective ; sign symptom alcohol withdrawal time initial consent Legal involvement could interfere study treatment . Individuals court order treatment eligible participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Alcohol</keyword>
	<keyword>Abuse</keyword>
	<keyword>Use</keyword>
	<keyword>Disorder</keyword>
	<keyword>Dependence</keyword>
	<keyword>Symptoms</keyword>
	<keyword>Alcoholic</keyword>
	<keyword>Alcoholism</keyword>
	<keyword>Prazosin</keyword>
	<keyword>Drug</keyword>
	<keyword>Medicine</keyword>
	<keyword>Medication</keyword>
	<keyword>Treatment</keyword>
	<keyword>Study</keyword>
	<keyword>Placebo</keyword>
	<keyword>Medical</keyword>
	<keyword>Management</keyword>
	<keyword>Craving</keyword>
	<keyword>Consumption</keyword>
	<keyword>Binge</keyword>
	<keyword>Drinking</keyword>
	<keyword>Drink</keyword>
	<keyword>Heavy</keyword>
</DOC>